Search clinical trials for: LEO 90105

Total 1694 results

LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects by Dermal Application of a LEO 29102

Atopic Dermatitis

United Kingdom
AVEO Pharmaceuticals, Inc.

No longer available

Protocol to Allow Continued Access of Ficlatuzumab to P05538 Patient

Mullerian Mixed Tumor of Ovary

United States
LEO Pharma

Completed

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

Atopic Dermatitis

United States, Canada, Australia
Queen's University
The Ottawa Hospital; University of Ottawa

Completed

Effectiveness and Efficiency of Two Models of Delivering Care to a Chronic Wound Population

Varicose Ulcer

Canada
LEO Pharma

Recruiting

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada, France, Germany, Japan, Poland, United Kingdom, Czechia, Spain, Romania, Hungary
LEO Pharma

Completed

Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children

Atopic Dermatitis

United States, Canada
LEO Pharma

Withdrawn

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese

Healthy

United Kingdom
LEO Pharma

Completed

Assessment of the Phototoxic Potential of LEO 29102 Cream

Atopic Dermatitis

France
LEO Pharma

Completed

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Actinic Keratosis

United States
LEO Pharma

Terminated

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Alopecia Areata

Denmark
LEO Pharma

Terminated

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Discoid Lupus Erythematosus

United States, France, Germany, Denmark
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up

Actinic Keratosis

United States
LEO Pharma
ICON plc

Completed

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

Healthy Volunteers

Netherlands
LEO Pharma

Completed

Multiple Dose Study With Incremental Dosing to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral Doses of LEO 32731 in Healthy Male Japanese Subjects.

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Actinic Keratosis

United States
University College, London

Terminated

Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic (LIO-C)

COVID19

United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Biological Effects of LEO 43204 in Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

Safety, Tolerability and Pharmacokinetics in AD Subjects and Healthy Subjects of Cutaneous Application of LEO 39652 Cream

Atopic Dermatitis

United Kingdom
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) (DELTA 2)

Chronic Hand Eczema

Belgium, Canada, Denmark, Germany, Netherlands, Poland, Spain
LEO Pharma

Completed

Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 1)

Chronic Hand Eczema

Canada, France, Germany, Italy, Poland, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

United States
LEO Pharma

Completed

Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream

Healthy Volunteers

Germany
LEO Pharma

Completed

LEO 27847 - A Study in Healthy Male Subjects

Healthy

United Kingdom
LEO Pharma

Completed

LEO 32731 - A Study in Healthy Male Subjects

Healthy Subjects

United Kingdom
LEO Pharma

Completed

Dermatopharmacokinetic Trial of LEO 80185 Gel

Psoriasis Vulgaris

Japan
LEO Pharma

Completed

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

Frontal Fibrosing Alopecia

United States
LEO Pharma

Completed

The Impact of Renal Impairment on the Pharmacokinetic and Pharmacodynamic of LEO 27847

Renal Impairment

Canada
LEO Pharma

Completed

LEO 22811 - Single Dose Bioavailability Study of Tablet Versus Oral Solution in Healthy Subjects

Healthy

United Kingdom
Centre Hospitalier de Saint-Brieuc
Rennes University Hospital

Unknown

Use of a Connected Companion in Children With Cystic Fibrosis (COMPANION-CF)

Chronic Disease | Cystic Fibrosis in Children

France
LEO Pharma

Completed

Efficacy and Safety of LEO 19123 Cream in the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada
LEO Pharma

Completed

LEO 22811 - A Phase 1, Double-Blind, Placebo-controlled, Single and Multiple Oral Dose Study in Healthy Subjects

Psoriasis Vulgaris

United Kingdom
LEO Pharma

Completed

LEO 27847 - Single Dose Bioavailability Study of Oral Solution Versus Tablet in Healthy Subjects

Healthy

United Kingdom
LEO Pharma

Completed

A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD

Atopic Dermatitis

Austria
Universidade Estadual de Londrina

Completed

Effects of Light Emitting Diodes (LED) Therapy in Rugby Athletes

Phototherapy

Brazil
LEO Pharma

Completed

A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

Psoriasis Vulgaris

Canada, France
VA Office of Research and Development

Active, not recruiting

LED Treatment to Improve Cognition and Promote Recovery in TBI (LED-TBI)

Traumatic Brain Injury | Posttraumatic Stress Disorder

United States
Spenshult Hospital
The Swedish Rheumatism Ass; County Council of Halland, Sweden

Unknown

Nurse-led Clinic for Patients With Rheumatic Diseases and Biological Treatment

Rheumatic Diseases

Sweden
LEO Pharma

Completed

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Scalp Psoriasis

United States
University of Alberta
Alberta Innovates Health Solutions

Completed

Intensive Motor Training After Perinatal Stroke to Enhance Walking

Perinatal Stroke

Canada
Fondazione Don Carlo Gnocchi Onlus

Completed

Efficacy of End-Effector Robot-Assisted Gait Training Combined With Robotic Balance Training in Subacute Stroke Patients

Stroke

Italy
LEO Pharma

Completed

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

Psoriasis Vulgaris

France
The Hong Kong Polytechnic University

Completed

The Effects of WBV on Muscle Stiffness and Reflex Activity in Stroke.

Stroke

Hong Kong
University of Dundee

Completed

Testing and Treating Hepatitis C in Community Pharmacies (SuperDOT-C)

Hepatitis C

United Kingdom
LEO Pharma

Completed

A Psoriasis Plaque Test With LEO 29102 Cream and Its Combination Products

Psoriasis Vulgaris

France
Indiana University
Purdue University

Not yet recruiting

Leg Heat Therapy in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction
New York Institute of Technology

Recruiting

Light Exposure on Pain in Hypermobile Ehlers-Danlos Syndrome (LEEDS)

Pain, Chronic | Ehlers-Danlos Syndrome

United States
University of Nove de Julho

Unknown

Photobiomodulation With Red and Infrared LED Device for Temporomandibular Dysfunction

Temporomandibular Disorder

Brazil
Southlake Regional Health Centre

Completed

Comparative Study of Two Brands of Heparin Already on the Market

Coronary Artery Bypass Grafting

Canada
University of Bergen
Glamox

Completed

Light Intervention for Adaptation to Night Work

Sleep | Sleep Deprivation | Shift-Work Related Sleep Disturbance

Norway

3

Subscribe